Funding

#Antibiotics #Drug development #Funding #Research

US researcher awarded $3.6 million to study antibiotic resistance

Sanford Burnham Prebys professor Andrei Osterman, Ph.D., has been awarded a $3.6 million grant from the National Institutes of Health (NIH) to expand current knowledge of antibiotic resistance, which will inform more precise antibiotic prescribing practices and help researchers develop drugs that are harder for bacteria to resist.   Context… Read More

#News

#Funding #Immunology / Virology & Vaccines #Life sciences #Research

£50m funding for new vaccine research building at Oxford University 

Oxford University has announced a £50 million funding commitment from Serum Life Sciences to establish The Poonawalla Vaccines Research Building at the University of Oxford.  What will it do?  The Poonawalla Vaccines Research Building will share infrastructure and support facilities with Oxford University Pandemic Sciences… Read More

#News

#Biosciences #Drug development #Funding #RNA #Technology #Therapeutics

Sixfold Bioscience completes $10.5 million seed financing 

Sixfold Bioscience (Sixfold), a company using computation and advanced chemistry to design RNA therapeutic delivery systems, has raised $10.5 million in its seed funding round, which will support the continued development of the company’s Mergo RNA therapeutics delivery platform.  Investors   Investors in the seed round included Cantos Ventures, Y Combinator, Lombard Street… Read More

#Business & Investment #News

#Biotechnology #Biotherapeutics #Clinical trials #Funding

Northwest Biotherapeutics announces $15 million financing    

Northwest Biotherapeutics, a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers in the United States, has announced the closing of a $15 million financing.  The company plans to use the funding to help accelerate its activities related to its brain cancer programme.    The financing is in the form… Read More

#News

#Collaboration #Drug development #Funding

Benchling announces $100 million funding and continued expansion 

Benchling is continuing its European expansion, following a strong year of growth. This expansion comes as Benchling reveals it has raised $100 million in Series F funding at a $6.1 billion valuation.   Context  The company achieved triple-digit year-over-year revenue growth in the market in its most recent fiscal… Read More

#News

#AI / data analytics / healthtech / informatics #AstraZeneca #Drug development #Funding #Research #Technology

Next wave of innovation: AstraZeneca £1bn R&D centre 

AstraZeneca has unveiled The Discovery Centre (DISC) in Cambridge, UK – a research and development (R&D) facility designed to the world’s highest environmental standards and accommodating over 2,200 research scientists.  The new £1 billion facility will include advanced robotics, high-throughput screening and AI-driven technology. It will support AstraZeneca’s focus… Read More

#News

#Antibodies #Biotherapeutics #Covid-19 #Data #Funding #Immunology / Virology & Vaccines

Twist Bioscience spins out Covid antibodies into Revelar Biotherapeutics

Twist Bioscience has launched Revelar Biotherapeutics to develop and commercialise an antibody that neutralises all known variants of concern of the SARS-CoV-2 virus in preclinical studies.   In addition, Revelar will have the ability to leverage the antibody discovery and optimisation platform of Twist Biopharma to license additional antibodies for up to five targets over the next four… Read More

#Covid-19 #News

Handshake
#Autoimmune disease #Collaboration #Drug development #Drug targets #Funding #Partnership

Agreement to develop drug target for multiple autoimmune diseases 

Affibody partnered with ACELYRIN to develop and commercialise izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple autoimmune diseases.   Izokibep is an antibody mimetic, IL-17A inhibitor designed to overcome the limitations of monoclonal antibodies. With extraordinary potency and small molecular size, izokibep can reach high drug exposure levels through a single subcutaneous… Read More

#News

#Assay #CRO #Funding #Technology

Gentronix set to double in size following £700k investment 

Gentronix, a UK-based contract research organisation (CRO) working in the field of genetic toxicology, has raised £700,000 in a funding round led by existing investor Mercia to support its continued growth.  The latest round, which includes a number of private investors, follows Gentronix’s recent acquisition of the Big Blue transgenic mutation… Read More

#News

#Biotechnology #Cancer research #Funding #Infectious diseases

SpyBiotech announces VP appointment and expansion of scientific team 

SpyBiotech, a biotechnology company with a vaccine platform technology targeting infectious diseases, cancer and chronic diseases, has appointed Simon Jones as VP of Finance and Operations, and expanded its scientific team with four new hires.   Jones takes up the permanent position from Vien Phan, who held the… Read More

#News

#Collaboration #Funding #Lead optimisation

Collaboration to develop oral targeted protein degrader therapies 

Dunad Therapeutics has entered a strategic collaboration and license agreement with Novartis to generate orally bioavailable covalent and protein degrading small molecule drugs.  Dunad will be responsible for programme execution up to lead optimisation, while Novartis will contribute target and ligand knowledge as well as access to assays… Read More

#News

#Cell and gene therapy #Cell therapy #Drug discovery #Funding

bit.bio receives $103 million for human cell production  

Human cell coding company bit.bio has closed a Series B financing of $103 million to accelerate the clinical development of the company’s cell coding technology opti-oxTM, a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells. … Read More

#News

#Antibiotics #Funding

ANTRUK spends largest ever sum on antibiotic research projects 

Antibiotic Research UK (ANTRUK) is funding seven new antibiotic research projects totalling £200,000, reportedly the largest sum it has ever awarded through its 2021 Small Research Grants / Career Development Awards scheme. The grants will fund essential academic research in both basic and applied sciences to help prevent another global pandemic,… Read More

#News

#Drug development #Funding #Health #Healthcare #Public health

UK budget plans: healthcare industry reaction 

In the Autumn 2021 budget delivered by UK Chancellor of the Exchequer, Rishi Sunak, on 27 October, the Government announced a range of measures designed to benefit UK science, business, and technology. This, at a time where the UK’s health service will need to tackle backlogs through the Winter… Read More

#News #Trending News

#Drug development #Drug discovery #Funding #Therapeutics

Researchers awarded $12 million for personalised asthma therapies

A group of researchers led by Indiana University School of Medicine’s Benjamin Gaston has been awarded a research programme project grant from the National Heart, Lung and Blood Institute. The award amounts to just over $12 million over the next five years and will fund the development of personalised… Read More

#News

#Biology #DNA #Funding #Life sciences

DNA Script raises $165M to accelerate enzymatic DNA printing platform  

DNA Script has raised $165 million in a Series C financing led by Coatue Management and Catalio Capital Management, whose representatives have joined as board observers. The new funds will be used to accelerate expansion and commercialisation of the company’s SYNTAX Platform and broaden the portfolio of products powered by EDS.  DNA Script… Read More

#News